Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06545591
Recruiting Observational

Predictive Role of sTREM in Endovascular Thrombectomy Outcomes

NCT06545591 · tracked via the Priya Life Science China tracker
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Phase
Observational
Started
2024-07-01
Last updated
2024-08-09

Condition(s) studied

Acute Ischemic Stroke

Study summary

Soluble triggering receptor expressed on myeloid cells (sTREM), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. This study is to investigatethe prognostic roles of sTREM (sTREM1 and sTREM2) in patients with ischemic stroke who underwent endovascular thrombectomy (EVT).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients \> 18 years old. * Patients with acute large vessel occlusion within 24 hours of onset who will receive endovascular treatment. Exclusion Criteria: * Impossibility of getting a blood sample. * Impossibility of performing the test (Invalid results). * Refusal to provide the informed consent by the patient/relative.

Primary outcome measure(s)

  • Dynamic changes in plasma levels of sTREM-1 and sTREM-2 following Endovascular Therapy — From baseline to immediately, 24 hours, 3 days, and 7 days after Endovascular Therapy
    Plasma levels of sTREM-1 and sTREM-2 will be quantified using the ELISA method.

Trial sites (1)

FacilityCityRegionStatus
Department of Neurology Xuzhou Jiangsu Recruiting

More The Affiliated Hospital of Xuzhou Medical University trials in China

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer Recruiting
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients Starting soon
BGT007H Cells for the Treatment of Refractory Digestive System Tumors Recruiting
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL Recruiting
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy Active, not recruiting

Other trials for the same condition

RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction Starting soon
Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Starting soon
Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS) Starting soon
Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06545591 on ClinicalTrials.gov ↗ ← All trials in China